

21 December 2022



The Nifty previous session ended 1.01% down at 18199.10. It opened positive followed by sell off across Index majors towards ending with a bearish engulfing. The Nifty closing below 18200 suggesting further weakness. Downside supports are placed around 18120 and 18050 levels. Chart pattern suggesting range bound oscillation with a negative bias in the price band of 18120-18500 is most likely. Midway resistance is placed around 18450 levels.

On the Nifty hourly chart, it reacted down exactly from the critical MA band placed around 18500 levels. leading indicators suggesting further decline towards 18120 and 18050 levels.

Nifty patterns on multiple periods suggesting; intraday recovery may again find sellers on rise, considering the bearish engulfing on daily. Massive resistance is placed in the price range of 18450-18500 levels. Hence, staying cautious on rise is advised.

Nifty Crucial Supports & Resistances-

Supports- 18120, 18050 Resistances- 18450, 18500

Open Positional Calls-

T+15 INST POSITIONAL SELL-

|Fut Segment| ITC @ 350-355, TGT- 325, Closing SL- above 370

T+15 INST POSITIONAL SELL-

|Fut Segment| SBIN @ 610-615, TGT- 575, Closing SL- above 635

T+15 INST POSITIONAL SELL-

|Fut Segment| CAN BANK @ 330-335, TGT- 295, Closing SL- above 355

T+15 INST POSITIONAL SELL-

|Fut Segment| M&M @ 1320-1340, TGT- 1230, Closing SL- above 1380

T+5 BUY-

|Cash Segment| TECH MAHINDRA @ 1025-1020, TGT- 1060, Closing SL- below 1000

T+3 BUY-

|Cash Segment| HINDALCO @ 452-450, TGT- 470, Closing SL- below 440

T+30 INST POSITIONAL SELL-

|Fut Segment| BANK OF BARODA @ 185-190, TGT- 150, Closing SL- above 210

T+30 INST POSITIONAL SELL-

|Fut Segment| BHARTI AIRTEL @ 830-840, TGT- 760, Closing SL- above 880

Nifty Intraday Chart



Market in Retrospect

The Indian benchmark indices opened higher but declined in trade amid high volatility on Wednesday.

Nifty index ended 1.01% lower, ended at 18,199. The broader markets represented by the Nifty 500 Index ended 1.26% lower, ending at 15,726. Among the sectorial indices, Nifty Pharma was the top gainer gaining 2.39%, followed by Nifty IT was higher by 0.53%. Nifty Realty was the top loser losing by 1.62%.

Divi'S Laboratories was the top gainer, gaining by 4.99%, followed by Apollo Hospitals and Cipla which gaining by 3.69% & 3.38%. Adani Enterprise was the top loser, losing by 6.32%, followed by Adani Ports & SE and Indusind Bank which losing by 3.01% & 2.19%.

Market Turnover (In Crore) 21-12-2022

Name	Last	Previous
NSE Cash	58490.46	46586.19
NSE F&O	24655357.28	21649929.00
BSE Cash	4,353.81	4,374.45
BSE F&O	*NA	177.67

FII Derivatives Flow (In Crore) 21-12-2022

Instrument	Purchase	Sale	Net
Index Future	5141.45	5726.93	585.48
Index Option	1704236.43	1700497.11	3739.32
Stock Future	12434.61	12233.15	201.46
Stock Option	15438.20	15343.81	94.39

Institutional Flow (In Crore) 21-12-2022

Institution	Purchase	Sale	Net
FII	4737.71	5856.82	1119.11
DII	6494.78	4737.41	1757.37

*Data not updated till 6:45PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Divi'S Laboratories	4.99	3.68	1455203	248780
Apollo Hospitals	3.69	2.14	877375	321323
Cipla	3.38	1.38	3224730	921734
Sun Pharma	1.75	0.53	2043630	1678817
Hcl Technologies	1.03	1.50	2878658	3089823

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Ultratech Cement	2.08	3.43	388167	298462
Bajaj Finserv	2.10	2.54	1397725	1217404
Indusind Bank	2.19	4.10	1495106	2316672
Adani Ports & SE	3.01	4.76	4660583	5126248
Adani Enterprises	6.32	3.79	3585883	1800284

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	61067.24	635.05	1.03	2.57	0.13	2.71	8.43
Nifty	18199.10	186.20	1.01	2.47	0.22	2.71	8.52
BSE M Cap	25480.94	362.19	1.40	3.46	1.53	1.15	5.99
BSE S Cap	28949.96	646.50	2.18	3.46	0.69	0.99	3.88
Nifty MC 100	31610.30	506.70	1.58	3.81	2.29	0.34	8.23
BSE Auto	29158.02	383.42	1.30	2.22	0.08	3.83	22.91
BSE Capgoods	34091.22	568.83	1.64	3.67	2.29	5.57	23.72
BSE FMCG	16435.79	182.66	1.10	1.59	3.54	1.14	23.36
BSE Metal	20324.43	201.52	0.98	3.02	3.54	6.95	6.87
BSE Oil&Gas	20267.35	382.22	1.85	1.68	3.24	4.37	18.49
BSE Healthcare	23600.27	519.19	2.25	0.43	1.19	2.20	3.80
BSE Power	4418.53	108.63	2.40	3.42	4.51	13.95	27.35
BSE Realty	3433.55	58.78	1.68	4.73	2.55	4.56	5.96
BSE ConsDur	39441.47	522.70	1.31	3.04	3.35	7.85	6.83
BSE Bank	48487.11	824.65	1.67	3.09	0.14	2.90	23.34
BSE IT	28730.36	66.21	0.23	3.49	2.21	5.03	19.97

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.67	0.01	0.21	5.68	3.97	4.11	151.41
UK	3.60	0.01	0.17	8.66	13.06	8.79	312.60
Brazil	6.16	0.08	1.23	7.90	1.96	2.02	32.05
Japan	0.48	0.07	17.65	90.48	94.33	85.33	805.66
Australia	3.73	0.00	0.05	10.76	3.90	1.66	133.02
India	7.29	0.01	0.16	0.12	0.45	0.73	12.65
Switzerland	1.48	0.05	3.49	28.78	47.66	14.63	770.14
Germany	2.30	0.01	0.26	18.45	15.25	21.40	850.98

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	82.82	0.06	0.08	0.45	1.17	3.43	8.71
USD Index	104.14	0.18	0.17	0.36	3.43	5.88	7.93
YUAN	6.98	0.01	0.21	0.37	2.71	1.06	8.66
GBP	1.21	0.01	0.65	2.59	2.38	7.40	8.73
EUR	1.06	0.00	0.09	0.64	3.63	7.90	5.95
YEN	131.84	0.11	0.08	2.76	7.81	9.27	13.46

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1596.00	48.00	3.10	17.61	35.60	8.59	30.43
Baltic Dirty	1951.00	92.00	4.50	6.16	20.66	29.98	143.57
SG Dubai HY	25.48	2.40	10.40	18.79	23.39	24.23	638.55

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	32849.74	92.20	0.28	3.69	2.52	8.83	7.45
Nasdaq	10547.11	1.08	0.01	6.30	4.33	6.00	31.25
S&P 500	3821.62	3.96	0.10	4.93	3.25	0.84	17.80
FTSE100	7433.49	60.48	0.82	0.86	0.74	2.67	1.83
CAC40	6517.75	66.77	1.04	3.17	1.77	8.06	6.43
DAX	13983.05	98.86	0.71	3.30	2.76	9.53	9.48
Mexico IPC	50139.42	193.32	0.39	0.38	2.77	6.70	3.74
Brazil Bovespa	106864.1	2124.36	2.03	3.21	2.63	4.53	1.29
Russian RTS	947.03	19.76	2.04	10.68	15.58	14.40	39.79
Japan Nikkei	26387.72	180.31	0.68	6.28	5.57	3.39	7.47
Hang Seng	19160.49	65.69	0.34	2.61	8.52	3.88	16.59
Taiwan Index	14234.40	64.37	0.45	3.43	1.49	1.32	19.98
Shanghai Comp	3068.41	5.36	0.17	3.40	0.54	1.56	15.36
KOSPI	2328.95	4.34	0.19	2.93	3.74	0.78	21.72
Malaysia KLCI	1462.55	4.77	0.33	1.39	1.01	1.06	2.01
Jakarta Comp	6820.66	52.35	0.77	0.28	3.43	5.11	4.06
Philippine SE	6520.80	62.68	0.97	1.43	1.84	2.82	9.02
Thai Exch	1609.94	5.50	0.34	1.43	0.55	1.44	0.76

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	77.47	1.29	1.69	0.31	2.77	6.53	9.00
BRENT Crude	81.37	1.40	1.75	1.58	6.54	5.25	16.59
Natural Gas	5.53	0.21	3.89	13.95	23.40	31.77	33.04

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1813.71	3.53	0.19	0.39	4.39	8.39	1.41
Silver(\$/Ounce)	23.90	0.24	1.00	0.10	14.73	22.25	6.23
Aluminium	2339.00	15.50	0.67	3.34	2.76	5.09	11.67
Copper	8333.75	30.50	0.37	1.37	3.62	6.49	11.93
Zinc	3120.50	68.50	2.24	6.75	3.23	0.76	7.51
Lead	2194.00	21.00	0.97	0.15	2.47	17.81	5.01

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	168.60	0.80	0.48	0.27	5.11	21.62	24.97
Cotton	87.46	0.38	0.43	7.48	9.63	7.02	0.76
Sugar	20.85	0.27	1.31	2.76	4.98	17.07	15.77
Wheat	752.75	2.25	0.30	0.47	8.00	17.75	4.96
Soybean	1486.75	7.00	0.47	0.12	3.12	1.24	20.53

Only 8 coal mines auctioned in fourth round of auctions

Out of 99 coal mines that were put on the block in the fourth round of the auction, just eight blocks have been auctioned successfully, Parliament was informed on Wednesday. Development of new mines are required towards Atmanirbhar Bharat to reduce import dependence. Coal demand of 1500 million tonne per annum (MTPA) is projected by the year 2030. The 99 mines were in states of Andhra Pradesh, Bihar, Chhattisgarh, Jharkhand, Madhya Pradesh, Maharashtra, Odisha, Telangana and West Bengal. Resettlement & rehabilitation of project affected families will be done as per prevailing norms of the state governments.

M3M acquires 350-acre land in Panipat for Rs 1500 crore

Real estate developer M3M has acquired 350-acre land in Panipat, Haryana for Rs 1500 crore in the biggest land deal of the country in recent times. The land originally belonged to the Ambience group, but Indiabulls Housing Finance, which had extended loans and had balance dues of over Rs 2,500 to the group, has been selling its properties to recover the money.

Mankind Pharma enters pet care segment with launch PetStar brand

Mankind Pharma has diversified into the pet care segment with the launch of PetStar brand. The first product was PetStar Dog Food. The PetStar food comes in different varieties like dry food, treats, gravy, among others. The brand aims to build and support the pet care ecosystem by offering pet food, medicine, supplements, and grooming products. Mankind Pharma on it strives to make PetStar a loved, palatable, nutritious and healthy food brand for pets such as dogs and cats. Mankind's PetStar food will be available in different flavours and manufactured in the UK, using European raw materials. PetStar food is produced as per the quality and safety standards of BRCGS (British Retail Consortium Global Standards) and the food is also tested in laboratories.

Auto components industry grows 34.8 pc to Rs 2.65 lakh crore in H1 FY23

India's auto components industry witnessed a 34.8 per cent growth to Rs 2.65 lakh crore in first-half of 2022-23, riding on domestic demand, particularly from the passenger vehicles segment. During the period, exports of components grew by 8.6 per cent to USD 10.1 billion (Rs 79.03 lakh crore), while imports climbed 17.2 per cent to USD 10.1 billion (Rs 79.8 lakh crore), Automotive Component Manufacturers Association of India (ACMA). There has been a demand shift towards SUVs, and the value proposition has also been enhanced.

Indian companies are paying up to 25% more for China APIs

India's pharmaceutical industry, which is dependent on China for active pharmaceutical ingredients (APIs), intermediates and bulk drugs, has been hit by the Covid-19 surge in that country. Key APIs have become 12-25% costlier in the past few days amid possible supply disruptions that may squeeze margins and raise drug prices, industry executives said. This could also lead to drug shortages, they warned. There's an upward trend in APIs of azithromycin, paracetamol, oral and injectable antibiotics.

China faces shortages of ibuprofen medicine, people line up outside factories

China is experiencing a sudden surge in coronavirus cases, just a couple of weeks after after the Xi-Jinping government eased the stringent Zero Covid Policy. Projections have suggested the world's second largest economy could now face an explosion of cases and more than a million deaths next year after the abrupt change in course. As reported by The Hong Kong Post, it is certain that the Chinese government was 'under-prepared' as it decided to end its zero-COVID policy abruptly after people held protests across the country. Now, Epidemiologist and health economist Eric Feigl-Ding has warned that the country is also facing shortage of basic ibuprofen medicine. People are directly going to the factories of the manufacturer and waiting in long line to buy them. The epidemiologist further said that if China has shortage, the rest of the world will have shortage.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Bambino Agro Industries Ltd	Cash dividend of INR1.60 effective 22-12-2022
Precision Wires India Ltd	Stock dividend of INR1.50 effective 22-12-2022
Globe Commercials Ltd	Stock dividend of INR2 effective 22-12-2022
ZIM Laboratories Ltd	Stock dividend of INR3 effective 22-12-2022

Domestic Events

- No events

Global Events

- The U.S. Initial Jobless Claims December 17, 2022.
- The U.S. GDP Growth Rate for Q3 2022.

Analyst Certification:

We /I, Jaydeb Dey Research Analyst(S) of SMIFS Limited (in short "SMIFS / the Company"), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
